Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:5:257-64.
doi: 10.2147/JPR.S27894. Epub 2012 Aug 14.

Liposomal bupivacaine: a review of a new bupivacaine formulation

Praveen Chahar  1 , Kenneth C Cummings 3rd
Affiliations

Liposomal bupivacaine: a review of a new bupivacaine formulation

Praveen Chahar et al. J Pain Res. 2012.

Abstract

Many attempts have been made to increase the duration of local anesthetic action. One avenue of investigation has focused on encapsulating local anesthetics within carrier molecules to increase their residence time at the site of action. This article aims to review the literature surrounding the recently approved formulation of bupivacaine, which consists of bupivacaine loaded in multivesicular liposomes. This preparation increases the duration of local anesthetic action by slow release from the liposome and delays the peak plasma concentration when compared to plain bupivacaine administration. Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy. Studies have shown it to be an effective tool for postoperative pain relief with opioid sparing effects and it has also been found to have an acceptable adverse effect profile. Its kinetics are favorable even in patients with moderate hepatic impairment, and it has been found not to delay wound healing after orthopedic surgery. More studies are needed to establish its safety and efficacy for use via intrathecal, epidural, or perineural routes. In conclusion, liposomal bupivacaine is effective for treating postoperative pain when used via local infiltration when compared to placebo with a prolonged duration of action, predictable kinetics, and an acceptable side effect profile. However, more adequately powered trials are needed to establish its superiority over plain bupivacaine.

Keywords: efficacy; liposomal bupivacaine; pharmacodynamics; pharmacokinetics; postoperative pain; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scanning electron microscope image of DepoFoam® containing bupivacaine. Image supplied courtesy of Pacira Pharmaceuticals, Inc, 5 Sylvan Way, Parsippany, NJ 07054.
Figure 2
Figure 2
Cross-sectional diagram of DepoFoam containing bupivacaine. Image supplied courtesy of Pacira Pharmaceuticals, Inc, 5 Sylvan Way, Parsippany, NJ 07054.
See this image and copyright information in PMC

References

    1. Acerbi A, Parisi D. The evolution of pain. In: Costa FA, Rocha LM, Costa E, Harvey I, Coutinho A, editors. Advances in Artificial Life; ECAL 2007: Proceedings of the 9th Annual Conference on Advances in Artificial Life; September 10–14, 2007; Lisbon, Portugal. Berlin: Springer; 2007. pp. 816–824.
    1. Loeser JD, Melzack R. Pain: an overview. Lancet. 1999;353(9164):1607–1069. - PubMed
    1. Breivik H. Pain management. Baillieres Clin Anaesthesiol. 1994;8(4):775–795.
    1. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol. 2007;21(1):65–83. - PubMed
    1. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging. 2008;3(2):273–278. - PMC - PubMed